Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02397018
Other study ID # Pro00059284
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2015
Est. completion date February 23, 2017

Study information

Verified date October 2019
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase one study investigating the safety of a single, intravenous infusion of banked allogeneic umbilical cord blood in subjects following an acute ischemic stroke. The cord blood infusion must be given within 3-10 days of the stroke. Follow up phone calls will occur at 1, 6, and 12 months post-infusion, and will include telephone surveys on post-stroke rehabilitation and functioning. A follow up clinic visit at 90 days will include a neurological exam, MRI, and blood tests.


Description:

The purpose of this study is to assess the safety of a single, intravenous infusion of banked allogeneic umbilical cord blood in subjects within 3-10 days following an acute ischemic stroke. The subjects will not be pre-treated with immunosuppressive agents. The primary objective is safety assessment and the secondary objectives are to determine which outcome measures can be used as primary and secondary endpoints for future randomized Phase 2 clinical trials, and to describe clinical responses, if any. All subjects will receive standard of care acute and rehabilitation treatments while enrolled in this study.

This is a multicenter Phase 1 safety study in patients 18-80 years of age who have sustained a recent ischemic stroke. A total of 10 subjects will be enrolled. Subjects will be given a series of baseline neurological assessments, blood tests, and MRI. Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells/kg. Umbilical cord blood will be administered intravenously as a single infusion between 3 and 10 days post-stroke. Subjects will be monitored for 6 hours post-infusion, and follow up will occur 24 hours later. Subsequent follow up phone calls will occur at 1, 6, and 12 months, and will include telephone surveys on post-stroke rehabilitation and functioning. A follow up clinic visit at 90 days will include a neurological exam, MRI, and blood tests.

Risks of cord blood infusion include infusion-related reactions such as anaphylaxis, urticaria, dyspnea, hypoxia, cough, wheezing, bronchospasm, nausea, vomiting, hives, fever, hypertension, hypotension, bradycardia, tachycardia, rigors, chills, infection, and hemoglobinuria. Less likely, long-term risks include transmission of infection or Graft vs Host Disease.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date February 23, 2017
Est. primary completion date February 23, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

An individual is eligible for inclusion if all of the following apply:

1. Is 18-80 years old

2. Has had a recent (within the past 9 days), acute, cortical, hemispheric, ischemic stroke in the middle cerebral artery (MCA) distribution without a midline shift as detected by magnetic resonance imaging (MRI) as a diffusion-weighted image (DWI) abnormality

3. Has a National Institutes of Health Stroke Scale (NIHSS) score of 8-15 (R) and 8-18 (L) at the time of enrollment with no more than a 4 point increase (worsening of score) from the baseline score compared to 24 hours prior to infusion

4. Subjects must have a platelet count >100,000/uL, hemoglobin >8gm/dl, and white blood cell count (wbc) >2,500/uL.

5. Subjects who received tissue plasminogen activator (tPA) or underwent mechanical reperfusion may be included in the study.

6. Is able to provide consent to study or consent is obtained from the subject's legally authorized representative

7. Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the investigator, they will not become pregnant during the course of the study

8. Is a good candidate for the trial, in the opinion of the investigator

9. Agrees to participate in follow up visits

10. Has an ABO/Rh matched umbilical cord blood unit with a minimum of 0.5 x 10^7 total nucleated cells (TNCC)/kg based on the pre-cryopreservation TNCC.

Exclusion Criteria:

An individual is ineligible to participate if any of the following apply.

Medical Conditions:

1. Has a medical history of neurological or orthopedic pathology with a deficit as a consequence that results in a modified Rankin Scale >1 before stroke or has a pre-existing cognitive deficit

2. Has clinically significant and/or symptomatic hemorrhage associated with stroke

3. Has new intracranial hemorrhage, edema, or mass effect that may place patient at increased risk for secondary deterioration when assessed prior to infusion

4. Has hypotension as defined as the need for IV pressor support of systolic blood pressure <90

5. Has isolated brain stem stroke

6. Has pure lacunar stroke

7. Requires mechanical ventilation

8. Requires a craniotomy

9. Has a serious psychiatric or neurological disease which could alter evaluation on functional or cognitive scales

10. Has an active systemic infection or is HIV positive

11. Has had an active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma

12. Has known coagulopathy such as Factor V Leyden, AntiPhospholipid Syndrome (APC), Protein C, Protein S deficiency, sickle cell, anticardiolipin antibody, or phospholipid syndrome

13. Has any concurrent illness or condition that in the opinion of the investigator might interfere with treatment or evaluation of safety

14. Has current or recent history of alcohol or drug abuse, or stroke associated with drug abuse

15. Pregnant as documented by urine or blood test

Concomitant or Prior Therapies:

1. Subjects currently receiving immunosuppressant drugs

2. History of prior transfusion reaction

3. Currently on dialysis

4. Recipient of bone marrow or organ transplant

5. Renal insufficiency with serum creatinine >2.0 mg/dL

6. Hepatic insufficiency (bilirubin >2.5mg/dL or transaminases >5x the upper limit of normal). Patients with Gilberts syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level.

7. Any previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy

8. Subjects participating in another interventional clinical trial of an investigational therapy within 30 days of screening

Other:

1. Pregnant or lactating women

2. Unable to be evaluated for follow up visits

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
allogeneic umbilical cord blood
Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina
United States Houston Methodist Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Joanne Kurtzberg, MD

Country where clinical trial is conducted

United States, 

References & Publications (1)

Laskowitz DT, Bennett ER, Durham RJ, Volpi JJ, Wiese JR, Frankel M, Shpall E, Wilson JM, Troy J, Kurtzberg J. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. Stem Cells Transl Med. 2 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events Number of subjects experiencing any study related Adverse Event (AE) during the 12-month follow-up period 12 months post-infusion for the last subject
Primary Graft Versus Host Disease The proportion of subjects experiencing Graft Versus Host Disease (GVHD) at Day 100 post-infusion 100 days
Secondary Change in modified Rankin Score The mean change in modified Rankin Score from baseline to 3 months post-infusion 3 months post-infusion for the last subject
Secondary Change in Infarct Volumes Describe changes in infarct volumes over the first 3 months post-stroke 3 months post-infusion for the last subject
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A